3/11
07:44 pm
meso
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast [Yahoo! Finance]
Low
Report
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast [Yahoo! Finance]
3/11
07:21 pm
meso
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Low
Report
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
2/27
03:31 am
meso
Mesoblast misses H1 estimates [Seeking Alpha]
Medium
Report
Mesoblast misses H1 estimates [Seeking Alpha]
2/26
08:02 pm
meso
Ryoncil® Profits Underpinning Substantial Growth Pipeline [Yahoo! Finance]
Medium
Report
Ryoncil® Profits Underpinning Substantial Growth Pipeline [Yahoo! Finance]
2/26
07:42 pm
meso
Ryoncil® Profits Underpinning Substantial Growth Pipeline
Medium
Report
Ryoncil® Profits Underpinning Substantial Growth Pipeline
2/20
07:00 am
meso
Mesoblast Financial Results and Corporate Update Webcast
Low
Report
Mesoblast Financial Results and Corporate Update Webcast
2/11
06:27 pm
meso
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Medium
Report
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
1/28
11:27 pm
meso
Ryoncil® Net Revenues Increase for the Quarter to US$30M [Yahoo! Finance]
Low
Report
Ryoncil® Net Revenues Increase for the Quarter to US$30M [Yahoo! Finance]
1/28
06:54 pm
meso
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Low
Report
Ryoncil® Net Revenues Increase for the Quarter to US$30M
1/26
06:45 pm
meso
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Medium
Report
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
1/18
07:01 pm
meso
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
Medium
Report
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
1/8
07:18 pm
meso
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M [Yahoo! Finance]
Low
Report
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M [Yahoo! Finance]
1/8
06:46 pm
meso
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
Medium
Report
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
1/4
03:04 pm
meso
ASX Growth Leaders With Strong Insider Confidence [Yahoo! Finance]
Low
Report
ASX Growth Leaders With Strong Insider Confidence [Yahoo! Finance]
1/1
06:02 pm
meso
Mesoblast Announces Changes to Board of Directors' Leadership Roles
Low
Report
Mesoblast Announces Changes to Board of Directors' Leadership Roles
12/29
08:21 pm
meso
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line [Yahoo! Finance]
Medium
Report
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line [Yahoo! Finance]
12/29
06:57 pm
meso
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Low
Report
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line